Do analysts rate REVB or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 754.70%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation & earnings, REVB or CTXR?

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revelation Biosciences N/A N/A -$8.91M -$12.31 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$1.67 N/A

Is REVB or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% Citius Pharmaceuticals N/A -59.57% -34.47%

Do analysts prefer REVB or CALC?

CalciMedica has a consensus price target of $50.00, indicating a potential upside of 2,461.48%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better earnings and valuation, REVB or CALC?

CalciMedica is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revelation Biosciences N/A N/A -$8.91M -$12.31 N/A CalciMedica N/A N/A -$29.56M -$6.80 N/A

Is REVB or CALC more profitable?

Revelation Biosciences' return on equity of -100.19% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% CalciMedica N/A -863.40% -155.24%

Which has stronger earnings & valuation, ADIL or REVB?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A Revelation Biosciences N/A N/A -$8.91M -$12.31 N/A

Is ADIL or REVB more profitable?

Revelation Biosciences' return on equity of -100.19% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% Revelation Biosciences N/A -100.19% -82.72%

Do analysts recommend SCNX or REVB?

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 336.05%. Given Scienture's stronger consensus rating and higher probable upside, research analysts clearly believe Scienture is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNX or REVB more profitable?

Scienture's return on equity of -53.51% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Revelation Biosciences N/A -100.19% -82.72%

Do analysts rate MBRX or REVB?

Moleculin Biotech presently has a consensus target price of $3.00, suggesting a potential upside of 286.10%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Moleculin Biotech is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MBRX or REVB?

Moleculin Biotech is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A Revelation Biosciences N/A N/A -$8.91M -$12.31 N/A

Is MBRX or REVB more profitable?

Revelation Biosciences' return on equity of -100.19% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A -143.51% -24.53% Revelation Biosciences N/A -100.19% -82.72%

Revelation Biosciences (REVB) Competitors

$0.98 -0.01 (-1.35%)

As of 11:46 AM Eastern

Compare

REVB vs. CTXR, CALC, ADIL, SCNX, and MBRX

Should you buy Revelation Biosciences stock or one of its competitors? Revelation Biosciences's main competitors and comparable companies include Citius Pharmaceuticals (CTXR), CalciMedica (CALC), Adial Pharmaceuticals (ADIL), Scienture (SCNX), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Revelation Biosciences (NASDAQ:REVB) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Revelation Biosciences has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 754.70%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

Citius Pharmaceuticals' return on equity of -59.57% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

In the previous week, Revelation Biosciences and Revelation Biosciences both had 2 articles in the media. Revelation Biosciences' average media sentiment score of 1.44 beat Citius Pharmaceuticals' score of 0.94 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Positive
Citius Pharmaceuticals	Positive

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to CalciMedica?

Revelation Biosciences (NASDAQ:REVB) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

CalciMedica has a consensus price target of $50.00, indicating a potential upside of 2,461.48%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

CalciMedica is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A

12.8% of Revelation Biosciences shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 28.3% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Revelation Biosciences' return on equity of -100.19% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
CalciMedica	N/A	-863.40%	-155.24%

In the previous week, CalciMedica had 4 more articles in the media than Revelation Biosciences. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 1.44 beat CalciMedica's score of 0.79 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Positive
CalciMedica	Positive

Revelation Biosciences has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Summary

CalciMedica beats Revelation Biosciences on 7 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Adial Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Revelation Biosciences' return on equity of -100.19% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Revelation Biosciences	N/A	-100.19%	-82.72%

In the previous week, Revelation Biosciences had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.89 beat Revelation Biosciences' score of 1.44 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
Revelation Biosciences	Positive

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

Adial Pharmaceuticals currently has a consensus target price of $15.63, suggesting a potential upside of 207.28%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Adial Pharmaceuticals is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Adial Pharmaceuticals beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Scienture?

Scienture (NASDAQ:SCNX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

In the previous week, Scienture had 2 more articles in the media than Revelation Biosciences. MarketBeat recorded 4 mentions for Scienture and 2 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 1.44 beat Scienture's score of 0.72 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Scienture	Positive
Revelation Biosciences	Positive

Scienture's return on equity of -53.51% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Revelation Biosciences	N/A	-100.19%	-82.72%

Scienture has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Scienture presently has a consensus target price of $1.50, suggesting a potential upside of 336.05%. Given Scienture's stronger consensus rating and higher probable upside, research analysts clearly believe Scienture is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.7% of Scienture shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Revelation Biosciences has lower revenue, but higher earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	32.85	-$41.51M	-$2.10	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

Summary

Scienture beats Revelation Biosciences on 10 of the 14 factors compared between the two stocks.

How does Revelation Biosciences compare to Moleculin Biotech?

Moleculin Biotech (NASDAQ:MBRX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Moleculin Biotech has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

Moleculin Biotech is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

In the previous week, Moleculin Biotech had 3 more articles in the media than Revelation Biosciences. MarketBeat recorded 5 mentions for Moleculin Biotech and 2 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 1.44 beat Moleculin Biotech's score of 0.72 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Positive
Revelation Biosciences	Positive

Revelation Biosciences' return on equity of -100.19% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Revelation Biosciences	N/A	-100.19%	-82.72%

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 18.0% of Moleculin Biotech shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Moleculin Biotech presently has a consensus target price of $3.00, suggesting a potential upside of 286.10%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Moleculin Biotech is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Moleculin Biotech beats Revelation Biosciences on 9 of the 13 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REVB vs. The Competition

Export

Metric	Revelation Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.90M	$12.52B	$7.20B	$12.67B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.08	797.25	275.02	25.43
Price / Sales	N/A	756.92	638.08	88.25
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.76	10.42	10.32	6.23
Net Income	-$8.91M	$2.84B	$3.50B	$358.31M
7 Day Performance	-2.88%	-3.55%	-2.41%	-1.59%
1 Month Performance	-7.64%	0.79%	0.22%	-2.89%
1 Year Performance	-87.25%	3.89%	24.17%	8.22%

Revelation Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REVB Revelation Biosciences	1.3921 of 5 stars	$0.98 -1.4%	N/A	-87.1%	$3.90M	N/A	N/A	10	Positive News
CTXR Citius Pharmaceuticals	2.4546 of 5 stars	$0.58 -3.4%	$5.00 +762.1%	-52.0%	$15.92M	N/A	N/A	20	News Coverage
CALC CalciMedica	4.3231 of 5 stars	$2.30 +13.9%	$50.00 +2,073.9%	-87.5%	$15.71M	N/A	N/A	30	Analyst Downgrade Short Interest Decrease
ADIL Adial Pharmaceuticals	3.0855 of 5 stars	$5.93 -10.8%	$15.63 +163.5%	-44.0%	$15.60M	N/A	N/A	20	Positive News
SCNX Scienture	3.0083 of 5 stars	$0.37 +0.9%	$1.50 +308.6%	-63.1%	$15.07M	$430K	N/A	N/A	Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REVB) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revelation Biosciences (REVB) Competitors

REVB vs. CTXR, CALC, ADIL, SCNX, and MBRX

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Summary

How does Revelation Biosciences compare to CalciMedica?

Summary

How does Revelation Biosciences compare to Adial Pharmaceuticals?

Summary

How does Revelation Biosciences compare to Scienture?

Summary

How does Revelation Biosciences compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB vs. The Competition

Revelation Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revelation Biosciences (REVB) Competitors

REVB vs. CTXR, CALC, ADIL, SCNX, and MBRX

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Which has more risk & volatility, REVB or CTXR?

Do analysts rate REVB or CTXR?

Which has stronger valuation & earnings, REVB or CTXR?

Is REVB or CTXR more profitable?

Does the media refer more to REVB or CTXR?

Do institutionals & insiders hold more shares of REVB or CTXR?

Summary

How does Revelation Biosciences compare to CalciMedica?

Do analysts prefer REVB or CALC?

Which has better earnings and valuation, REVB or CALC?

Do insiders and institutionals believe in REVB or CALC?

Is REVB or CALC more profitable?

Does the media refer more to REVB or CALC?

Which has more risk & volatility, REVB or CALC?

Summary

How does Revelation Biosciences compare to Adial Pharmaceuticals?

Which has more risk & volatility, ADIL or REVB?

Is ADIL or REVB more profitable?

Does the media prefer ADIL or REVB?

Do insiders & institutionals hold more shares of ADIL or REVB?

Which has stronger earnings & valuation, ADIL or REVB?

Do analysts recommend ADIL or REVB?

Summary

How does Revelation Biosciences compare to Scienture?

Does the media prefer SCNX or REVB?

Is SCNX or REVB more profitable?

Which has more volatility & risk, SCNX or REVB?

Do analysts recommend SCNX or REVB?

Do insiders and institutionals hold more shares of SCNX or REVB?

Which has better valuation & earnings, SCNX or REVB?

Summary

How does Revelation Biosciences compare to Moleculin Biotech?

Which has more risk and volatility, MBRX or REVB?

Which has higher valuation & earnings, MBRX or REVB?

Does the media prefer MBRX or REVB?

Is MBRX or REVB more profitable?

Do institutionals and insiders hold more shares of MBRX or REVB?

Do analysts rate MBRX or REVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB vs. The Competition

Revelation Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools